Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247778 | 0.86 | ALDH1A1 (0.54) | ALDH1A1TYK2FABP3FABP4HPGD | |
| Bromide SCHEMBL27753498 | 0.84 | ALDH1A1 (0.52) | ALDH1A1TYK2FABP3FABP4HPGD | |
| SCHEMBL103586 | 0.84 | ALDH1A1 (1.00) | ALDH1A1TYK2HPGDFEN1NPC1 | |
| SCHEMBL30676249 | 0.83 | FABP3 (0.55) | ALDH1A1TYK2FABP3FABP4HPGD | |
| SCHEMBL13100052 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TYK2FABP3FABP4HPGD | |
| SCHEMBL484445 | 0.83 | FABP3 (0.55) | ALDH1A1TYK2FABP3FABP4HPGD | |
| Methane SCHEMBL28290707 | 0.81 | ALDH1A1 (0.95) | ALDH1A1TYK2HPGDFEN1NPC1 | |
| SCHEMBL1397518 | 0.81 | TSHR (0.51) | ALDH1A1TYK2FABP3FABP4HPGD | |
| SCHEMBL11782277 | 0.80 | TYK2 (0.46) | ALDH1A1TYK2FABP3FABP4HPGD | |
| SCHEMBL31504897 | 0.80 | TYK2 (0.46) | ALDH1A1TYK2FABP3FABP4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637427-B2 | ALDH-2 inhibitor compounds and methods of use | AMYGDALA NEUROSCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250381182-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12351569-B2 | ALDH-2 inhibitor compounds and methods of use | AMYGDALA NEUROSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250197400-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | INTEILIKINE LLC | 2025-06-19 | — | — | US | disclosed |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4540237-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | Amygdala Neurosciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540228-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | Amygdala Neurosciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12018009-B2 | ALDH-2 inhibitor compounds and methods of use | AMYGDALA NEUROSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2023244563-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244574-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-6380387-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | HOFFMANN-LA ROCHE INC. | 2002-04-30 | — | — | US | disclosed |
| CN-1323295-A | Azabicyclic compounds for modulating cell adhesion inhibition | AVENTIES PHARMACEUTICAL LTD (GB) | 2001-11-21 | — | — | CN | disclosed |
| EP-1114028-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | Aventis Pharma Limited (GB) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001042225-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| CN-1281430-A | N-alkanoylphenylalanine derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-24 | — | — | CN | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000015612-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LIMITED (GB) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381182-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | ALDH1A1 1/4885TYK2 3431/4885FABP3 3048/4885 |
| US-20250197400-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | PIK3CA, PIK3CD, PDPK1 | ALDH1A1 3088/4885TYK2 632/4885FABP3 4807/4885 |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ALDH1A1 2185/4885TYK2 451/4885FABP3 3704/4885 |
| US-12351569-B2 | ALDH-2 inhibitor compounds and methods of use | ALDH1A1, ALDH2, ALDH3A1 | ALDH1A1 1/4885TYK2 3476/4885FABP3 3119/4885 |
| US-12637427-B2 | ALDH-2 inhibitor compounds and methods of use | ALDH3A1, ALDH1A1, ALDH1A2 | ALDH1A1 2/4885TYK2 2918/4885FABP3 4080/4885 |
| US-12018009-B2 | ALDH-2 inhibitor compounds and methods of use | ALDH1A1, ALDH2, ALDH3A1 | ALDH1A1 1/4885TYK2 3431/4885FABP3 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.